The inflationary cap on list price growth will impact drug makers, which have already seen their net prices stagnate in recent years and even enter negative territory. It will also lower Medicare beneficiaries' out-of-pocket spend and affect price negotiations between PBMs and drug makers.
Subscribe to:
Post Comments (Atom)
< + > Real-Time Pharma Insights: Philip Poulidis on Scaling ODAIA AI – Life Sciences Today Podcast Episode 41
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Philip Poulidis, ...
No comments:
Post a Comment